
Bria-IMT Plus Checkpoint Inhibition Is Safe and Yields Clinical Benefit in Pretreated Metastatic Breast Cancer
Treatment with the off-the-shelf, targeted, cell-based immunotherapy Bria-IMT (SV-BR-1-GM) in combination with an immune checkpoint inhibitor demonstrated favorable safety, tolerability, and evidence of clinical benefit in heavily pretreated patients with …